IMNM Surges 14.5% on Volatile Intraday Rally: What’s Fueling the Momentum?

Summary
• Immunome (IMNM) surges 14.48% to $19.565, hitting 52-week high of $19.655
• Intraday range spans $17.0 to $19.655, with turnover of 1.46M shares
• Biotech sector gains traction as AMGN leads with 2.29% rise

Immunome’s explosive intraday rally has captured market attention, with the stock surging 14.48% to $19.565. The move coincides with a broader biotech sector upswing, led by Amgen’s 2.29% gain. High implied volatility in options and a near-52-week high price suggest a mix of speculative fervor and sector-wide optimism. Traders are now dissecting technical indicators and options activity to gauge sustainability.

Options Volatility and Sector Sentiment Drive IMNM’s Surge
The 14.48% intraday jump in Immunome’s stock is driven by a confluence of factors. First, the options market shows extreme implied volatility (243.70%–271.17%) on key call contracts expiring Dec 19, indicating aggressive bullish positioning. Second, the biotech sector’s broader momentum—evidenced by Amgen’s 2.29% rise—suggests a risk-on environment for healthcare innovation. While no company-specific news was released, the stock’s proximity to its 52-week high ($19.655) has triggered algorithmic and retail buying, with traders capitalizing on the breakout from Bollinger Bands’ upper boundary.

Biotech Sector Gains Momentum as AMGN Leads Charge
The biotech sector is in a bullish phase, with Amgen (AMGN) surging 2.29% and Immunome (IMNM) nearly hitting its 52-week high. This momentum reflects investor confidence in healthcare innovation, particularly in therapies targeting immune disorders and rare diseases. While Immunome’s rally is more speculative, Amgen’s gains are underpinned by its diversified pipeline and recent regulatory progress. The sector’s strength suggests a broader risk appetite, though individual stocks like IMNM remain volatile due to options-driven flows.

Options and ETF Plays for IMNM’s Volatile Trajectory
• MACD: 0.786 (Signal: 0.910, Histogram: -0.125) – bearish divergence
• RSI: 46.75 – neutral
• Bollinger Bands: $14.95 (Lower) – $19.62 (Upper) – near overbought
• 200D MA: $10.57 – price far above

IMNM’s technicals suggest a short-term bearish trend but long-term bullish setup. Key levels to watch: $19.65 (52-week high) and $17.28 (20D MA). The stock’s proximity to its upper Bollinger Band and elevated implied volatility (243.70%–271.17%) make it a high-risk, high-reward play. Two top options from the chain:

• IMNM20251219C20
- Type: Call
- Strike: $20
- Expiry: 2025-12-19
- IV: 271.17% (extreme volatility)
- Leverage: 4.50% (moderate)
- Delta: 0.6017 (moderate sensitivity)
- Theta: -0.1478 (rapid time decay)
- Gamma: 0.0337 (moderate price sensitivity)
- Turnover: 9,936 (high liquidity)
- Why: High IV and turnover suggest strong speculative demand. A 5% upside (to $20.54) would yield a 27.7% payoff (max(0, $20.54 - $20)).

• IMNM20251219C21
- Type: Call
- Strike: $21
- Expiry: 2025-12-19
- IV: 223.52% (high volatility)
- Leverage: 6.11% (high)
- Delta: 0.5389 (moderate sensitivity)
- Theta: -0.1278 (rapid time decay)
- Gamma: 0.0421 (high price sensitivity)
- Turnover: 320 (moderate liquidity)
- Why: High leverage and gamma make this ideal for a sharp breakout. A 5% upside (to $20.54) would yield a 21.6% payoff (max(0, $20.54 - $21)).

Aggressive bulls should consider IMNM20251219C20 into a break above $19.65.

Backtest Immunome Stock Performance
To run an event-based back-test I first need to be clear on how we should define the “14 % intraday surge.” Typical ways are:1. Close-to-close jump ≥ 14 % (today’s close vs. yesterday’s close). 2. Intraday high ≥ 14 % above the previous close (high/prev-close - 1 ≥ 14 %). 3. Open-to-close jump ≥ 14 % (close/open - 1 ≥ 14 %).Could you confirm which definition you’d like to use? (If you’re unsure, I can recommend one and explain why.)

IMNM at Pivotal Juncture: Breakout or Correction?
Immunome’s 14.48% surge has brought it to the brink of its 52-week high, with technicals and options data pointing to a volatile crossroads. While the stock’s long-term bullish setup (200D MA at $10.57) remains intact, short-term bearish divergence in MACD and overbought RSI suggest caution. Traders should monitor the $19.65 level for a breakout confirmation and watch Amgen’s 2.29% rally for sector sentiment. A sustained close above $19.65 could trigger a parabolic move, but a pullback to the 20D MA ($17.28) would test conviction. Act now: Buy IMNM20251219C20 if $19.65 breaks, or short-term traders should target $17.28 as a potential support test.